Supreme Court: Spouse Cannot Withdraw Consent for Mutual Divorce After Settlement Agreement  ||  Supreme Court Suspends PC Act Sentence of Former Minister Anosh Ekka, Flags Overlapping CBI Cases  ||  Supreme Court: Magistrate’s Probe Order Can’t be Quashed on Accused’s Defence  ||  Delhi High Court: No Adverse Inference if Handwriting Sample Refused Without Section 73 Disclosure  ||  J&K&L HC: Bank Officials Not Entitled to Section 197 CrPC Protection Despite Public Servant Status  ||  Kar HC Orders CBI Probe into 53-Acre Land Acquisition, Citing Alleged Monumental Fraud & Conspiracy  ||  Supreme Court Grants Probation to Convicts; Rules Fine-Only Cases Also Eligible  ||  SC Disposes Plea on Allied Health Course Moratorium After NCAHP Issues 2026–27 Guideline  ||  Supreme Court Grants Promotion Relief to Employee Denied Relaxation, Calling it Discrimination  ||  Patna HC: Tender Lapses if Not Extended on Time & Delay Cannot be Cured by Repeated Representations    

India Patent Office Dismisses Compulsory License Application of Lee Pharma - (21 Jan 2016)

Indian Patent Office has dismissed application of Lee Pharma for a compulsory licence to make a copy of AstraZeneca's antidiabetes drug saxagliptin, which is branded Onglyza.

Tags : INDIAN PATENT OFFICE   LEE PHARMA  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved